Biocon, a global biopharma company based in India, reported a 63.4% decline in consolidated net profit for the fourth quarter of FY26, amounting to ₹126 crore compared to ₹344 crore in the same quarter last year. Despite this significant drop, the company's revenue from operations saw a modest increase of 2.26%, reaching ₹4,517 crore. The EBITDA margin also faced a decline, falling by 200 basis points to 23%. For the full fiscal year 2026, Biocon's consolidated net profit stood at ₹386 crore, reflecting a 61.9% decrease year-on-year, while revenue increased by 10.9% to ₹16,927 crore. Kiran Mazumdar-Shaw, the executive chairperson, stated that the company closed FY26 on a strong note despite a complex geopolitical environment, citing a 13% growth in operating revenue when excluding the one-time impact of previous generic sales. The integration of Biocon's biosimilars and generics businesses has reportedly strengthened its financial position and global presence. Following the announcement, Biocon's stock rose by 2.43%, trading at ₹391.90 on the Bombay Stock Exchange.